Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aptose Bioscns (NQ: APTO ) 0.4052 +0.0052 (+1.30%) Streaming Delayed Price Updated: 3:56 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Aptose Bioscns < Previous 1 2 3 4 5 Next > Aptose Biosciences: Q3 Earnings Insights November 09, 2023 Via Benzinga Aptose Reports Results for the Third Quarter 2023 November 09, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting November 02, 2023 Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib October 30, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Expert Ratings for Aptose Biosciences September 07, 2023 Via Benzinga Analyst Expectations for Aptose Biosciences's Future May 09, 2023 Via Benzinga Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session October 30, 2023 Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash. Via Benzinga Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 October 26, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th October 23, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference October 16, 2023 Company to Hold Clinical Update Webcast; Details Forthcoming From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Present at the Cantor Global Healthcare Conference September 18, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical September 06, 2023 — TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax — From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 24, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire RBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To Know August 11, 2023 Via Benzinga Aptose Reports Results for the Second Quarter 2023 August 10, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023 July 27, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance June 26, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Stocks That Hit 52-Week Lows On Wednesday July 26, 2023 Wednesday saw 59 companies set new 52-week lows. Via Benzinga Aptose Presents Highlights from Clinical Update June 10, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Biosciences Provides Update on Reverse Stock Split June 05, 2023 Common Shares to begin trading on adjusted basis June 6 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023 May 31, 2023 EHA Abstract on Tuspetinib and Venetoclax Recently Published From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Enters into $25 Million Committed Equity Facility May 25, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket May 24, 2023 Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent #11653972 for "Medical Systems And Methods (For Resecting And... Via Benzinga Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders May 23, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire 3 Stocks With 1,000% Upside Potential May 21, 2023 If you're an investor comfortable with speculative bets, analysts are price targeting these stocks with 1000% upside. Via InvestorPlace Aptose Reports Results for the First Quarter 2023 May 08, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference May 04, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023 April 24, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference April 10, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium March 28, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.